Insmed Goes Full Steam Ahead With Bronchiectasis Candidate
Top-Line Phase II Data Impress For INS1007
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.
